Welcome to our dedicated page for Bio-Key Intl SEC filings (Ticker: BKYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BIO-key International, Inc. (NASDAQ: BKYI) SEC filings page provides direct access to the company’s regulatory disclosures, including annual and quarterly reports, current reports on Form 8-K, registration statements, and other key documents. These filings offer detailed insight into BIO-key’s identity and access management (IAM) and biometric authentication business, financial condition, risk factors, and capital markets activity.
In its S-1 registration statement, BIO-key outlines its role as an IAM platform provider for enterprise and large-scale customer and civil ID solutions. The filing describes the PortalGuard and PortalGuard IDaaS platforms, identity-bound biometrics, and the company’s biometric and authentication hardware portfolio. Investors can review this document to understand the structure of BIO-key’s business, its revenue sources from software licenses, services, and hardware, and its approach to large-scale biometric deployments.
Current reports on Form 8-K document material events such as financing transactions, warrant exercise agreements, secured promissory notes, Nasdaq listing compliance notices, and earnings announcements. For example, recent 8-K filings describe a warrant inducement transaction, a senior secured promissory note, and Nasdaq correspondence regarding the minimum bid price requirement for BKYI shares.
Through this page, users can also access proxy materials like the definitive proxy statement (DEF 14A), which covers matters submitted to shareholders, including director elections, auditor ratification, and equity compensation plans. These documents provide additional context on BIO-key’s governance and shareholder approvals.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents such as 10-Ks, 10-Qs, S-1s, and 8-Ks. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly, while AI-generated overviews help readers quickly identify information on topics such as revenue composition, financing terms, listing status, and risk disclosures. Users can also review insider and major holder information through Forms 3, 4, and 5 when available, with AI explanations that clarify the significance of reported transactions.
BIO-key International, Inc. (BKYI) filed its Definitive Proxy Statement (DEF 14A) for the 2025 Annual Meeting of Stockholders, scheduled for August 8 2025 at 10:00 a.m. (ET) at the company’s Holmdel, NJ headquarters. The record date is June 20 2025, when 6,848,775 common shares were outstanding, with each share entitled to one vote and no cumulative voting rights.
Shareholders will vote on six proposals: (1) election of five directors to serve until the 2026 meeting; (2) ratification of Bush & Associates CPA LLC as independent registered public accounting firm for FY 2025; (3) an advisory “say-on-pay” vote on executive compensation; (4) an amendment to the 2023 Stock Incentive Plan; (5) an amendment to the 2021 Employee Stock Purchase Plan; and (6) other routine business. Boxes for a preliminary proxy, confidential treatment, additional materials, and soliciting material are all unchecked, confirming that this filing is the definitive statement.
The proxy materials, together with the company’s Form 10-K for the year ended December 31 2024, were first mailed on or about June 27 2025. Registered shareholders may vote in person, by mail, telephone, or internet; beneficial owners must follow their broker’s instructions. Brokers lack discretionary authority to vote uninstructed shares on Proposals 1, 3, 4, or 5, potentially resulting in broker non-votes for those items.
The filing includes a detailed table of contents covering governance, principal stockholders, executive and director compensation, and full text of the amended stock plans (Appendices A & B). No filing fee was required. Aside from the requested plan amendments, the proxy does not disclose new financial metrics, acquisitions, or other extraordinary actions.